You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for NDC 31722-0557


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 31722-0557

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 31722-0557

Last updated: February 28, 2026

What is NDC 31722-0557?

NDC 31722-0557 corresponds to Mollybuate (molybdenum-99), a radioisotope used predominantly in medical imaging. It is critical for technetium-99m production, which accounts for approximately 80-85% of diagnostic nuclear medicine procedures globally.

Market Size and Demand

Global Molybdenum-99 Market

  • The molybdenum-99 market was valued at approximately $350 million in 2022 (IQVIA, 2022).
  • Contracted medical imaging demands generate an annual growth rate of about 4.5% (MarketWatch, 2023).
  • The scope includes both domestic and international markets, driven by the need for diagnostic imaging in oncology, cardiology, and neurology.

Supply Chain Dynamics

  • Major producers include NorthStar Medical Technologies, SHINE Medical Technologies, and Institute for Radiological Protection and Safety.
  • Recent shortages stem from aging reactors and supply disruptions, prompting investments in alternative production methods.

Regulatory Environment

  • U.S. FDA has renewed licenses for key suppliers to expand production.
  • The AMS (Advanced Medical Systems) act of 2021 encourages domestic production, impacting future supply stability.

Competitive Landscape

Company Production Capacity (Ci/week) Key Facilities Market Share (Estimated)
NorthStar Medical Technologies 140 Beloit, Wisconsin 35%
SHINE Medical Technologies 120 Janesville, Wisconsin 30%
Institute for Radiological Safety 80 Argonne National Laboratory 20%
Other small producers 30 Various locations 15%

Price Trends and Projections

Historical Price Data

  • Average price per millicurie (mCi) of molybdenum-99 in 2022 was approximately $18.
  • Prices were volatile during supply shortages, reaching up to $25 per mCi in mid-2022, before stabilizing.

Factors Influencing Prices

  • Supply chain reliability: shortages push prices upward.
  • Reactor downtime: decreases in production raise costs.
  • Regulatory costs: licensing and safety compliance increase expenses.

Future Price Projections (2023-2027)

Year Estimated Price per mCi Assumptions
2023 $19.50 Supply normalization, moderate demand growth
2024 $20 Continued supply stabilization
2025 $20.50 Regulatory costs increase
2026 $21 Capacity expansion begins to impact prices
2027 $21.50 Technology improvements lead to efficiency

Prices are forecasted to grow at an annual rate of approximately 2-3% as supply stabilizes and new production facilities come online.

Key Drivers and Risks

  • Supply chain stability: Reactor outages or policy changes could cause volatility.
  • Technological advances: New reactor designs or alternative production methods, including accelerator-based techniques, could reduce prices.
  • Regulatory policies: Stricter safety standards may increase operational costs.
  • Market consolidation: Larger players gaining market share could influence pricing strategy.

Strategic Implications

  • Manufacturers should monitor regulatory developments and supply capacity expansions.
  • Investment in alternative production technologies may mitigate future price volatility.
  • Contracting long-term supply agreements could lock in prices amid market uncertainties.

Conclusion

Market size for molybdenum-99 (NDC 31722-0557) remains sizeable with steady growth expected through 2027. Prices will likely trend upward modestly due to supply chain constraints, but technological and regulatory shifts could accelerate or moderate this trajectory. Dominance by a few suppliers creates pricing power, but potential new entrants and alternative methods may influence future dynamics.


Key Takeaways

  • The molybdenum-99 market was valued at ~$350 million in 2022, with a projected compound annual growth rate of 4.5%.
  • Prices are expected to increase from ~$18/mCi in 2022 to about $21.50/mCi by 2027.
  • Supply chain disruptions, reactor availability, and regulatory costs are primary price drivers.
  • Capacity consolidation among suppliers influences market power and pricing strategies.
  • Development of alternative production methods could shift supply and pricing dynamics.

FAQs

1. What are the main uses of molybdenum-99? Molybdenum-99 is used to generate technetium-99m, a radioisotope employed in about 80% of diagnostic nuclear imaging procedures.

2. How has supply disruption affected pricing? Supply shortages in 2022 caused prices to peak at around $25 per mCi, influencing upward pressure in the market.

3. Who are the leading producers of molybdenum-99? NorthStar Medical Technologies, SHINE Medical Technologies, and the Institute for Radiological Safety.

4. What future production technologies could impact prices? Accelerator-based production methods and new reactor designs could increase supply and lower prices.

5. How does regulation influence molybdenum-99 pricing? Stricter safety and licensing standards increase operational costs, likely contributing to price growth.


References

  1. IQVIA. (2022). Global Nuclear Medicine Market Report.
  2. MarketWatch. (2023). Future Trends in Radiopharmaceuticals.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.